Determination of factors influencing the outcome of radioiodine therapy in patients with Graves' disease;Bestimmung von Einflussgrossen fur den Therapieerfolg der Radioiodtherapie bei Patienten mit Morbus Basedow

NuklearMedizin

Volumn 37, Issue 3, 1998, Pages 83-89

  Sabri, O ^a   Schulz, G ^a   Zimny, M ^a   Schreckenberger, M ^a   Zimny, D ^a   Wagenknecht, G ^a   Kaiser, H J ^a   Dohmen, B M ^a   Bares, R ^a   Bull U ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

131I uptake; Graves' disease; Radioiodine therapy; Therapeutic half life of 131I; Thyreostatic medication; Thyroid volume

Indexed keywords

IODINE 131; RECEPTOR ANTIBODY; THYROID HORMONE RECEPTOR; ANTITHYROID AGENT; LIOTHYRONINE; RADIOACTIVE IODINE; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; HALF LIFE TIME; HISTOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; THYROID GLAND; TIME; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOTHERAPY DOSAGE; THYROID GLAND; THYROXINE; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 0032063806     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632331     Document Type: Article

References (36)

1. Alevizaki CC, Alevizaki-Harhalaki MC, Jkkos DG. Radioiodine-131 treatment of thyrotoxicosis: Dose required for and some factors affecting the early introduction of hypothyroidism. J Nucl Med 1985; 10: 450-4.
2. Becker DV, Hurley JR. Zanzonico PB, Kusic Z. Antithyroid drugs given during I-131 treatment maintain clinical control of hyperthyroidism and reduce whole body radiation. Endocrinol [Suppl] 1998; 121: abstr. 23.
3. Becker W, Borner W, Reiners C. Roedler HD. Die Radiojodtherapie der Immunhyperthyreose in Abhangigkeit vom Lebensalter. Dtsch med Wschr 1988. 113: 954-61.
4. Benker G, Kotulla P, Kendall-Taylor P, Emrich D, Reinwein D. TSH-binding inhibiting antibodies in hyperthyroidisin: Relationship to clinical signs and hormone levels. Clin Endocrinol 1989; 30: 19-28.
5. Berg GEB, Michanek AMK, Holmberg ECV, Fink M, Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996; 37: 228-32.
6. 131I) therapy. Eur J Nucl Med 1984; 9: 464-6.
7. Cunnien AJ, Hay ID, Gorman CA, Offord KP. Scanlon PW. Radioiodine-induced hypothyroidism in Graves' disease: Factors associated with the increasing incidence. J Nucl Med 1982; 32: 978-83.
8. De Bruin TWA, Croon CDL, De Klerk JMH, Van Isselt JW Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J Int Med 1994; 236: 507-13.
9. Dederichs B, Otte R, Klink JE, Schicha H. Volumenreduktion der Schilddruse nach Radiojodtherapie bei Patienten mit Schild-drusenautonomie und Morbus Basedow. Nuklearmedizin 1996; 35: 164-9.
10. Emrich D. Editorial. Muß die hohe Hypothyreoserate nach Radioiodtherapie einer immunogenen Hyperthyreose in Kauf genommen werden? Nuklearmedizin 1997; 36: 5.
11. Farrar JJ, Toft AD, Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinel 1991; 35: 207-12.
12. Flury B. Riedwyl H. Faktorenanalyse. In: Angewandte multivariate Statistik. Stuttgart: Fischer 1983; 135-49.
13. Giambarresi L, Jacobs A. Radioprotectants. In: Military Radiobiology. Conklin J. Walker R (eds.). Orlando (Flonda, USA): Academic Press 1987; 265-301.
14. Guhlmann CA, Rcndl J. Börner W. Radiojodtherapie der funktionellen Autonomie und des M. Basedow. Nuklearmedizin 1995; 34: 20-3
15. Harbert JC Radioiodine therapy of hyperthyreoidism. In: Nuclear Medicine Therapy. Harbert JC (ed.). Stuttgart: Georg Thieme Verlag 1987; 1-36.
16. Hoffman DA. Late effects of I-131 therapy in the United States. In: Radiation Carcinogenesis. Boice JD, Fraument JF (eds.). New York: Raven Press 1984; 273.
17. 131I) therapy for hyperthyroid Graves' disease. Endocrinol Japon 1991; 38: 429-33.
18. Kung AW-C, Yau C-C, Cheng AC-K, The action of methimazolc and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism Thyroid 1995; 5: 7-12.
19. 131Iod während einer Radioiodtherapie. Nuklearmedizin 1997; 36: 87-92.
20. Moser E, Pickardt CR, Mann K, et al. Ergebnisse der Radiojodbehandlung von Patienten mit immunogener und nichtimmunogener Hyperthyreose bei Anwendung unterschiedlicher Herddosen. Nuklearmedizin 1988; 27: 98-104.
21. Mukuta T, Tamai H, Oshima A, Morita T, Matsubayashi S, Fukata S, Kuma K. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin. Clin Endocrinol 1994; 40: 215-9.
22. 131J bei der Radiojodbehandlung der Schilddrüsenautonomie. Nuklearmedizin 1991; 30: 71-6.
23. Nüchel C, Boddenberg B, Schicha H, Die Bedeutung des Radiojodtests für die Berechnung der Therapiedosis bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 1993; 32: 91-8.
24. Nygaard B, Hegedus BNL, Gervil M, et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Int Med 1995; 238: 491-7.
25. 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 186-93.
26. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H, Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism. results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996; 26: 59-63.
27. 131I-Therapie mit 150 Gray beim Morbus Basedow. Nuklearmedizin 1997; 36: 81-6.
28. Reiners C. Radioiodine Treatment of Basedow's Disease: Interference and Influence Factors, Risk Estimation. Exp Clin Endocrinol 1991; 97: 275-85.
29. Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years' experience with Graves' disease. Arch Intern Med 1979; 139: 651-3.
30. Schicha H. Behandlung mit Radiojod bei immunogener Hyperthyreose. In: Schilddrüse 1987, Behandlungsstrategien und ihre Ergebnisse bei Schilddrusenerkrankungen. Pickardt CR, Pfannenstiel P. Weinheimer B (eds.). Stuttgart: Georg Thieme Verlag 1989; 76-85.
31. Schicha H. Radiojodtherapie - neuester Stand: Nichtimmunogene Hyperthyreose. Akt Endokr Stoffw 1992; 13: 71-9.
32. Schicha H. Therapie mit radioaktiven Stoffen. In: Nuklearmedizin. Büll U, Schicha A. Biersack H-J, Knapp WH, Reiners Chr, Schober O (eds.). Stuttgart, New York: Georg Thieme Verlag 1996; 460-87.
33. Schicha H. Stellungnahme zum Editorial, Nuklearmedizin 1997; 36: 6.
34. 131I and antithyroid drugs: A prospective study. J Nucl Med 1979; 20: 1263-7.
35. 131lodine therapy. In: Nuclear Medicine. Clinical Demands on Nuclear Medicine. Schmidt HAE, Emrich D (eds.). Stuttgart. New York: Schattauer 1987; 526.
36. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995; 5: 243-7.